Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Some topical cannabinoid therapies could be a safe and effective treatment for patients with atopic dermatitis (AD) says a ...

Atopic dermatitis (AD), the most common form of eczema, is a chronic inflammatory skin condition that leads to irritation and redness. The National Eczema Association estimates th ...

If you have atopic dermatitis (AD), also known as eczema, then you know the struggle: You climb into bed ready to catch some zzz's, but can't sleep because of the intense, relentless itching. Thanks ...

Underlying social and economic barriers in the U.S. may play a significant role in the higher rates of atopic dermatitis.

Dupilumab treatment of atopic dermatitis resulted in long-term skin improvements linked to changes in skin’s the molecular composition.

Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis when applied ...

Skin microbes do more than coexist—they shape immune responses, repair tissue, and influence gene expression across your ...

A patch test for atopic dermatitis helps identify triggers and confirms diagnosis. Learn about self-testing and specialists ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Discover expert-relief solutions for managing atopic dermatitis, from breakthrough treatments to daily habits that prevent ...